Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 370 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Kidney Transplant Recipient Clear all
Completed Phase 2 Interventional

A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients

NCT01780844
View directory record Official record
Conditions
Kidney Transplantation
Interventions
ASKP1240, Tacrolimus, Mycophenolate Mofetil (MMF), Basiliximab, Methylprednisone, Prednisone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Jul 21, 2026, 6:33 PM EDT
Terminated Phase 3 Interventional Results available

Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients

NCT05220397
View directory record Official record
Conditions
Kidney Transplant Recipient
Interventions
Janssen Ad26.CoV2.S Vaccine, Reduction in Immunosuppression Medication, Maintenance in Immunosuppression Medication
Biological · Other
Lead sponsor
Mark Stegall
Other
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Jul 21, 2026, 6:33 PM EDT
Completed Phase 4 Interventional Results available

Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients

NCT04529005
View directory record Official record
Conditions
Shock, Surgical, Shock, Hypotension and Shock, Kidney Transplant; Complications, Intraoperative Hypotension, Postoperative Hypotension
Interventions
Angiotensin II
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Jul 21, 2026, 6:33 PM EDT
Recruiting Not applicable Interventional

Use of CGM in Kidney Transplant Recipients

NCT04783441
View directory record Official record
Conditions
Kidney Transplant; Complications, Diabetes Mellitus, Type 2, Insulin Dependent Diabetes
Interventions
Dexcom G6, Dexcom G6 blinded sensor
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 21, 2026, 6:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Correlation of Molecular Biomarkers With Biopsy Findings and Outcomes in Renal Transplant Recipients

NCT02463253
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 82 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Jul 21, 2026, 6:33 PM EDT
Withdrawn Phase 2 Interventional

Selective CD28 Blockade in Renal Transplant Recipients

NCT04903054
View directory record Official record
Conditions
Kidney Transplantation, Renal Transplant Recipients
Interventions
Lulizumab, Tacrolimus, Thymoglobulin®, Methylprednisolone, Mycophenolate Mofetil, Prednisone
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Jul 21, 2026, 6:33 PM EDT
Terminated Phase 2 Interventional Results available

Belatacept to Prevent Organ Rejection in Kidney Transplant Patients

NCT00346151
View directory record Official record
Conditions
Renal Transplant
Interventions
Belatacept, Sirolimus, Anti-thymocyte globulin, methylprednisolone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
San Francisco, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Jul 21, 2026, 6:33 PM EDT
Completed Phase 4 Interventional

Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation

NCT00685061
View directory record Official record
Conditions
Renal Transplantation
Interventions
Thymoglobulin, Campath-1H, Daclizumab
Drug
Lead sponsor
University of Miami
Other
Eligibility
16 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Jul 21, 2026, 6:33 PM EDT
Completed Phase 1 Interventional Results available

Subcutaneous Abatacept in Renal Transplant Recipients

NCT05975450
View directory record Official record
Conditions
Kidney Transplant Recipient
Interventions
Abatacept 125Mg/Ml Syringe
Drug
Lead sponsor
Idelberto Badell
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jul 21, 2026, 6:33 PM EDT
Not listed Phase 1 Interventional

Modification of the "Edmonton Protocol" to Allow for Successful Islet Transplantation From a Single Pancreas and Extension of the "Edmonton Protocol" to Kidney Transplant Recipients

NCT00021580
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
human cadaveric islet cell transplantation
Procedure
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 6:33 PM EDT
Recruiting Phase 4 Interventional

Empagliflozin Treatment in Kidney Transplant Recipients

NCT06013865
View directory record Official record
Conditions
Kidney Transplant, Chronic Kidney Disease
Interventions
Empagliflozin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
19 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
5
States / cities
Hines, Illinois • Iowa City, Iowa • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 21, 2026, 6:33 PM EDT
Completed No phase listed Observational

Associating Renal Transplantation With the ITN Signature of Tolerance

NCT01516177
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
8
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Jul 21, 2026, 6:33 PM EDT
Completed Phase 2 Interventional

Reduced Calorie Diet Intervention in Kidney Transplant Recipients

NCT00994838
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
reduced calorie diet
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Jul 21, 2026, 6:33 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Treg Therapy in Subclinical Inflammation in Kidney Transplantation

NCT02711826
View directory record Official record
Conditions
Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant, Living Kidney Donor
Interventions
Polyclonal Regulatory T Cells, Everolimus, Tacrolimus, Mycophenolate mofetil, Mycophenolic acid, Acetaminophen, Diphenhydramine, Biopsy, Kidney, Blood Draw, Leukapheresis, IS regimen conversion
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Jul 21, 2026, 6:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Protective Immunity Project 01

NCT00788021
View directory record Official record
Conditions
Kidney Transplantation, Immunity, Immunosuppression
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 59 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced Jul 21, 2026, 6:33 PM EDT
Completed No phase listed Observational

Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival

NCT00531921
View directory record Official record
Conditions
Heart Transplantation, Kidney Transplantation, Liver Transplantation, Lung Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 70 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Ithaca, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Jul 21, 2026, 6:33 PM EDT
Recruiting Phase 2 Interventional

REgulatory T Cell Therapy to Achieve Immunosuppression REduction

NCT06552169
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI
Drug · Biological
Lead sponsor
Singulera Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Phoenix, Arizona • Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jul 21, 2026, 6:33 PM EDT
Completed No phase listed Observational

Quality of Life in Pediatric Transplant Recipients

NCT00209196
View directory record Official record
Conditions
Kidney Transplantation, Liver Transplantation, Heart Transplantation, Lung Transplantation, Heart-Lung Transplantation
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
11 Years to 18 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2015 · Synced Jul 21, 2026, 6:33 PM EDT
Not listed Phase 4 Interventional

Veloxis de Novo Kidney Transplant ECSWD

NCT03828682
View directory record Official record
Conditions
Kidney Transplantation, Immunosuppression
Interventions
Tacrolimus Extended Release Oral Tablet [Envarsus], Mycophenolate Mofetil, Mycophenolic Acid Oral Product, Tacrolimus, Methylprednisolone, Prednisone, Rabbit Anti-Human T-Lymphocyte Globulin Injectable Solution [Thymoglobulin]
Drug
Lead sponsor
Simon Tremblay, PharmD, PhD
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Jul 21, 2026, 6:33 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients

NCT00472082
View directory record Official record
Conditions
Kidney Transplantation, Chronic Kidney Failure
Interventions
efalizumab
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 26, 2014 · Synced Jul 21, 2026, 6:33 PM EDT
Completed Not applicable Interventional Results available

Effects of Personalized Physical Rehabilitation in Kidney Transplant Recipients

NCT02409901
View directory record Official record
Conditions
Kidney Transplant
Interventions
Exercise Rehabilitation
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Jul 21, 2026, 6:33 PM EDT
Recruiting Phase 1Phase 2 Interventional

CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients

NCT07096453
View directory record Official record
Conditions
Kidney Transplant; Complications, CMV
Interventions
Cytogam
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Jul 21, 2026, 6:33 PM EDT
Recruiting Phase 1Phase 2 Interventional

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

NCT05896839
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Metastatic Basal Cell Carcinoma, Metastatic Carcinoma in the Skin, Metastatic Melanoma, Metastatic Merkel Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Unresectable Basal Cell Carcinoma, Unresectable Melanoma, Unresectable Merkel Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Kidney Biopsy, Magnetic Resonance Imaging, Nivolumab, Prednisone, Sirolimus
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
26
States / cities
La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 21, 2026, 6:33 PM EDT
Completed Phase 4 Interventional

Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression

NCT04786067
View directory record Official record
Conditions
Kidney Transplant Immunosuppression
Interventions
Belatacept
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 21, 2026, 6:33 PM EDT